Hemostemix Announces Ongoing Phase II CLI Trial Abstract Accepted for Presentation by Canadian Society for Vascular Surgery
02 juil. 2019 08h30 HE
|
Hemostemix Inc.
CALGARY, Alberta, July 02, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company developing and commercializing...